Bispecific antibody-drug conjugates (ADCs) targeting dual tumor-associated antigens (TAAs) offer advantages in fighting against cancer. These include
-
the ability to simultaneously target multiple tumor-driven proteins, potentially overcoming drug resistance.
-
recognize cells co-expressing both targets to increase tumor specificity and reducing off-target toxicity.
-
the combination of two targets increases the internalization and thus tumor killing.
Biocytogen’s RenLite-based BsADC platform
-
BsADC developed from RenLite mice
Advantages of Biocytogen’s BsADC platform
-
RenLite-derived common light chain antibodies are easy to assemble into BsAb with low mismatch rate and ideal physiochemical properties.
-
Combined with target gene knockout strategy, RenLite KO mice can generate antibodies with increased diversity, potentially against novel epitopes and with cross-species reactivity.
-
Rapid generation of high-quality BsAbs/BsADCs for high-throughput in vitro and in vivo screening
Off-the-shelf TAA-targeting antibodies available for flexible plug & play
20+ BsADC programs available for partnership
Poster
AACR 2022: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy
World ADC San Diego2022:YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy
PEGS-EU 2022:YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy
AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy
AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy
AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity
AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET
AACR 2023: Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer
AACR 2023: A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy
AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1
AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate
IO Summit EU 2023: YH013, a Common Light Chain Bispecific ADC Targeting EGFR and MET, Improves Preclinical Efficacy Over Its Parental Single-Targeting ADCs